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Abstract. Oxidative stress and apoptosis have been reported to play major roles in the pathogenesis of Type 2 Diabetes 
Mellitus (T2DM) through insulin resistance and β-cell dysfunction. Naringin is a citrus derived flavonoid that has 
been reported for its antioxidant properties. Even though effects of naringin in T2DM related oxidative stress has been 
reported, varying dose concentration in oxidative stress and mechanism of action involving T2DM related apoptosis is 
far-fetched. This research studied the effects of naringin at varying dose concentration on apoptosis, biomarkers of organ 
function and oxidative stress in high fat diet/low-streptozotocin-induced  T2DM in albino Wistar rats. Diabetic rats 
were treated with naringin at 50mg/kg, 100mg/kg and 200mg/kg body weight for 21 days. Some biomarkers of organ 
function and oxidative stress in the animals were assayed using spectrophotometric techniques. The levels of expression 
of caspases and apoptotic regulators  were quantified using semi-quantitative reverse transcriptase  polymerase  chain 
reaction (RT PCR). Enzyme - linked immunosorbent assay was used to determine inducible nitric oxide synthase (iNOS) 
level. Naringin treatment shows a dose dependent significant (p<0.05) reduction in the plasma concentration of γ-
glutamyltransferase, alkaline phosphatase and aspartate aminotransferase. Increasing dosage of Naringin significantly 
(p<0.05) reduced lipid peroxidation, glutathione- s-transferase, glutathione peroxidase and glutathione reductase activities 
in the liver. Naringin treatment also showed a significant (p<0.05) increase in the expression of caspase 3 and 
reduction in BCL-2 as against the diabetic control. In addition, there was dose dependent decrease in plasma CO2 
concentration and increase in the plasma iNOS concentration as compared to the diabetic control. This result highlights 
positive effect of naringin as an antioxidant, its role in apoptosis and also reverting the effects of organ damage in type 2 
diabetes. 
INTRODUCTION 
Type 2 diabetes (T2DM) is a bipolar disease characterized by hyperglycaemia through insulin resistance and 
insulin secretion defects (1). T2DM is a major public health problem with increasing prevalence with the metabolic 
disorder estimated by the World Health Organization to hit a prevalence of over 380 million people globally by 
2025 [2]. Insulin resistance and β-cell dysfunction in T2DM has been linked to overproduction of reactive oxygen 
species (ROS), hyperglycemia and lipid accumulation and eventual occurrence of increased apoptosis and loss of 
insulin integrity [2]. Excess glucose from hyperglycemia also reacts with plasma proteins leading to ROS 
production  through  formation  of glycation  end  products  [3].  This increase  in  ROS  with concurrent decrease 
in plasma antioxidant is a major cause of oxidative DNA damage and insulin resistance in diabetic patient  [4]. 
Also, there have been  reports suggesting increased  apoptosis in  T2DM thus building possible relationship 
between apoptosis, β-cell dysfunction and oxidative stress [5]. Oxidative stress induced by hyperglycemia has been 
described to activate apoptosis through the intrinsic apoptotic pathway [6]. 
Complications encountered from the use of synthetic drugs as a form of T2DM have accelerated the use of 
encouraged the use of natural products like flavonoids. Some of these complications include hypoglycaemia and 
drug resistance [7]. Flavonoids including naringin have been explored for various properties in treatment of 
metabolic disorders. Naringin is a flavone glycoside and an aglycone of naringenin that gives grapefruit its bitter 
taste [8]. Naringin has been reported for its antioxidant property but its role in apoptosis linked T2DM is 
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unclear. This study, therefore, investigated the effects of naringin on oxidative stress and apoptosis in HFD/low 
STZ-induced experimental model of T2DM in rats. 
MATERIALS AND METHODS 
Chemicals 
Streptozotocin  (STZ) was purchased from Sigma-Aldrich, Missouri, U.S.A while Metformin however  was 
gotten  from  Swipha  Pharma,  Lagos,  Nigeria.  Naringin  was  obtained  from  Hunan  Kang  Biotechnology 
Company, Hunan Province, P. R China. All other chemicals used in this study were of Sigma-Aldrich, Missouri, 
U.S.A standard. 
Animals 
Thirty male albino rats of average weight of 170±20g were used for this experiment. Animals were housed in an 
animal room under normal temperature (22 ± 2 °C) with 12 hour light and dark cycle. The animals were allowed to 
acclimatise  for  three  weeks  before the commencement  of  the study.  The experiment approved by the 
institutional ethical review committee was carried out according to the guidelines of the committee in Covenant 
University, Ota, Ogun State, Nigeria. 
Experimental design 
The rats were divided into six experimental groups and maintained on their respective diets for a period of 9 
weeks with weight gain recorded weekly. Five of the groups were fed with High fat diet (HFD) with 45% fat 
while the last group was fed with normal pellet diet. 
• Group A, Diabetic Control: Rats fed with HFD. 
• Group B, Diabetic rats treated with 50mg/kg Naringin: Rats fed with HFD 
• Group C, Diabetic rats treated with 100mg/kg Naringin: Rats fed with HFD 
• Group D, Diabetic rats treated with 200mg/kg Naringin: Rats fed with HFD 
• Group E, Diabetic rats treated with 150mg/kg Metformin: Rats fed with HFD 
• Group N, Normal Control: Rats fed with normal diet. 
Animal treatment and sample collection 
After four weeks of feeding, the HFD fed groups were administered intraperitoneally with 30mg/kg body weight 
streptozotocin (STZ) twice in two weeks while the control group was administered the vehicle, 1ml/kg body weight 
0.1M citrate buffer (10). Fasting blood glucose was checked a week after the second dose of STZ had been 
administered. Naringin treatment was then administered for 21 days. Sample collection and preparation was done 
as described by Rotimi et al.,[9]. 
Determination of Plasma Inducible Nitric Oxide Synthase (iNOS) 
Plasma inducible nitric oxide synthase (iNOS) concentration was however determined by enzyme-linked 
immunosorbent assay (ELISA) using kit from Hangzhou east biopharm, China. 
Determination of biomarkers of organ damage 
Some biomarkers of organ damage in plasma including urea, creatine kinase, lactate dehydrogenase, υ- 
glutamyltransferase,  α–amylase,  alkaline  phosphatase,  alanine  aminotransferase,  aspartate  aminotransferase 
were assayed spectrophotometrically using kits from BioSino Biotechnology & Science Inc., Changping District 
Beijing, China. 
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Determination of Antioxidant enzymes 
Antioxidant enzyme activities were assayed using spectrophotometric method. Glutathione reductase was 
determined using the method of Mavis and Stellwagen [11]. Glutathione peroxidase was determined according to 
the method of Rotruck et al. [12]. Glutathione-S-transferase was determined according to the method of Habig 
et al. [13]. Superoxide dismutase was determined according to the method of Marklund and Marklund[14]. Lipid 
peroxidation was determined according to the method of Buege and Aust [15] while glutathione concentration was 
determined according to the method of Ellman [16]. 
Expression of Hepatic Apoptotic Genes 
Template RNA extracted from the liver using the Aidlab EASYspin Plus RNA extraction kit from Beijing, 
China.  Reverse  transcriptase  polymerase  chain  reaction  (RT-PCR)  was  carried  out  using  the  Transgen 
EasyScript one-step RT-PCR Supermix from China. All reactions were carried out on ice and manufacturer’s 
instructions were duly followed using the method initially described by Rotimi et al. [9]. 
The forward (F) and reverse (R) primers used and their sequences are listed in the table below: 
TABLE 1: Gene Specific Primer sequences 
 
Gene 5’-3’ Sequence 
β-Actin Forward: GTCAGGTCATCACTATCGGCAAT 
Reverse: AGAGGTCTTTACGGATGTCAACGT 
BCL-2 Forward: TTTTGCTGAGTTACCGGCGA  
Reverse: GCCACAAGGGTAGCCAGAAT 
Caspase 3 Forward: GAGCTTGGAACGCGAAGAAA  
Reverse: TAACCGGGTGCGGTAGAGTA 
Caspase 9 Forward: GCGCGACATGATCGAGGATA 
Reverse: TCTCCATCAAAGCCGTGACC 
 
Statistical Analysis 
Data was analysed using Mean± SEM of five replicates in each group. Analysis of Variance (ANOVA) was 
carried out to test for the level of homogeneity at p˂0.05 among the groups while Duncan’s Multiple Range Test 
(MRT) was used to separate the heterogeneous groups. 
RESULTS 
Levels of reduced glutathione (GSH), TBARS, glutathione S-transferase (GST), glutathione reductase (GRx) 
and glutathione peroxidase (GPx) were assayed in the heart, liver, brain, testes and kidney. The levels of 
TBARS, GST, GRx and GPx were significantly (p<0.05) increased in diabetic control group compared to 
normal group. Naringin caused a significant (p<0.05) dose-dependent reduction of levels of TBARS, GST, GRx and 
GPx in all the organs. GSH levels was however higher in the liver, kidney, testes and brain of normal control 
compared to negative control group with the heart showing an opposite effect. Treatment with 100 and 200mg/kg 
naringin slightly increased the GSH levels in the liver to a similar level in normal control. Naringin treatment 
caused an increase in the brain and testes with no change observered in the GSH levels of the kidney. 
Plasma biomarkers of organ damage including creatine kinase (CK), alanine aminotransferase (ALT), Lactate 
dehydrogenase (LDH), aspartate aminotransferase, alkaline phosphatase and γ-glutamyltransferase and urea 
were also assayed. There was a significant (p<0.05) increase in aspartate aminotransferase (AST), alkaline 
phosphatase (ALP), urea and γ-glutamyltransferase (γ-GGT) in diabetic control compared to normal control group. 
Naringin treatment significantly (p<0.05) reduced the activities of AST, ALP and γ-GGT. Although not significant, 
increases were observed in lactate dehydrogenase and creatine kinase levels in diabetic control as compared  to  
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normal  groups.  50 and 200mg/kg  naringin  treatment  significantly  (p<0.05)  reduced  the concentration of plasma 
urea to a normal level as compared to the diabetic control. 
TABLE 2. Effects of naringin on oxidative stress in rat organs 
a) Effects of Naringin on Thiobarbituric Acid Reactive Substances (mM/mg protein) 
 
 Liver Kidney Testes Brain Heart 
Diabetic Control 28.23±0.66
e
 29.43±1.13
e
 57.15±2.39
e
 61.51±6.04
c
 53.80±1.62
c
 
50mg/Kg bw 25.25±0.32
d
 23.59±0.19
d
 47.24±0.35
d
 49.62±0.47
b
 47.22±0.38
bc
 
100mg/Kg bw 22.72±0.26
c
 22.08±0.22
cd
 43.59±0.46
cd
 46.28±0.50
b
 42.13±1.34
bc
 
200mg/Kg bw 21.51±0.15
bc
 20.16±0.25
bc
 41.09±0.36
bc
 42.96±0.73
ab
 36.42±0.60
b
 
Metformin 20.02±0.26
b  18.49±0.18
ab  38.53±0.54
ab
 39.28±0.32
ab
 32.65±0.67
b
 
Normal Control 16.07±1.00
a  17.02±0.27
a
 35.18±0.85
a
 35.43±0.73
a  17.17±11.18
a
 
 
b) Effects of Naringin on reduced glutathione (mmol/mg protein) 
 
 Liver Kidney Testes Brain          Heart 
Diabetic Control 0.02±0.00
a
 0.05±0.00
a
 0.03±0.00
a
      0.05±0.00
a
        0.04±0.01
a
 
50mg/Kg bw 0.02±0.00
ab
 0.05±0.00
a
 0.04±0.00
a
 0.06±0.01
ab
 0.04±0.01
a
 
100mg/Kg bw 0.03±0.00
bc
 0.05±0.01
a
 0.04±0.01
a
 0.06±0.01
ab
 0.03±0.00
a
 
200mg/Kg bw 0.03±0.00
bc
 0.05±0.00
a
 0.04±0.01
a
 0.06±0.01
ab
 0.02±0.00
a
 
Metformin 0.03±0.00
c
 0.05±0.01
a
 0.05±0.01
a
 0.06±0.01
ab
 0.03±0.00
a
 
Normal Control 0.03±0.00
bc
 0.08±0.01
b
 0.07±0.01
b
 0.09±0.01
b
 0.03±0.00
a
 
 
c) Effects of Naringin on glutathione S-transferase (U/mg protein) 
 
 Liver Kidney Testes Brain Heart 
Diabetic Control 0.17±0.01
f
 0.14±0.01
e
 0.73±0.05
d
 0.39±0.01
e
 0.09±0.00
e
 
50mg/Kg bw 0.15±0.00
e
       0.1±0.00
d
 0.56±0.01
c
      0.3±0.01
d
 0.06±0.00
d
 
100mg/Kg bw 0.13±0.00
d
 0.08±0.00
c
  0.52±0.01
bc
 0.23±0.00
c
 0.05±0.00
c
 
200mg/Kg bw 0.11±0.00
c
  0.07±0.00
bc
  0.49±0.01
bc
 0.2±0.00
bc
 0.02±0.00
b
 
Metformin      0.1±0.00
b
 0.06±0.00
b
 0.44±0.01
b
 0.17±0.00
b
 0.01±0.00
a
 
Normal Control 0.06±0.01
a
 0.05±0.00
a
 0.34±0.05
a
 0.13±0.02
a
 0.01±0.00
a
 
 
d) Effects of Naringin on glutathione peroxidase (U/mg protein) 
 
     Liver   Kidney       Testes   Brain   Heart 
Diabetic Control 0.21±0.01
e
 0.22±0.01
bc
 0.37±0.01e 0.42±0.02
e
 0.52±0.01
f
 
50mg/Kg bw 0.18±0.00
d
 0.19±0.01
ab
 0.31±0.00d 0.36±0.00
d
 0.46±0.01
e
 
100mg/Kg bw 0.17±0.00
cd
 0.2±0.02
abc
 0.28±0.00c 0.34±0.00
cd
 0.44±0.00
d
 
200mg/Kg bw 0.16±0.00
bc
 0.16±0.01
a
 0.26±0.00
bc
 0.32±0.00
bc
 0.42±0.01
c
 
Metformin 0.15±0.00
b
 0.19±0.01
ab
 0.24±0.00ab 0.29±0.00
ab
 0.38±0.00
b
 
Normal Control 0.13±0.00
a
 0.23±0.01
c
 0.22±0.00a 0.26±0.00
a
 0.36±0.01
a
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e) Effects of Naringin on glutathione reductase (U/mg protein) 
 
       Liver     Kidney      Testes      Brain Heart 
Diabetic Control 0.13±0.01e 0.20±0.01e 0.20±0.04c 0.32±0.03
d
    0.13±0.01c 
50mg/Kg bw 0.10±0.00d 0.16±0.00d 0.11±0.00b 0.21±0.00c       0.10±0.00b 
100mg/Kg bw 0.09±0.00cd 0.14±0.00cd 0.09±0.00ab 0.19±0.01bc       0.08±0.00ab 
200mg/Kg bw 0.08±0.00c 0.13±0.00bc 0.07±0.00ab 0.16±0.00abc       0.07±0.00ab 
Metformin 0.06±0.00b 0.12±0.00b 0.05±0.00ab 0.14±0.00ab       0.06±0.00b 
Normal Control 0.04±0.00a 0.09±0.01a 0.03±0.00a 0.12±0.00a 0.02±0.02a 
 
Values are expressed as mean ± SEM (n=5). Values in the same column for same parameter with different superscripts are 
significantly different at p˂0.05. 
TABLE 3. Effects of Naringin on Biochemical organ damage 
 
 Alanine 
Aminotrans
ferase 
Lactate 
Dehydrogena
se (U/L) 
γ- 
glutamyltran
sferase (U/L) 
Creatine 
Kinase (U/L) 
Alkaline 
Phosphatase 
(U/L) 
Aspartate 
Aminotransferase 
(U/L) 
Diabetic Control 3.33±1.41a  68.01±9.58a 4.37±0.38e 42.73±3.51a  100.40±17.43b    66.63±10.19c 
50mg/Kg bw 6.28±2.19a 67.09±11.55a 2.76±0.00d 42.73±3.50a     77.20±16.89ab    27.49±1.00b 
100mg/Kg bw 8.73±6.90a 66.32±10.45a 2.30±0.21cd 42.73±3.49a     66.32±8.18a    21.14±1.01ab 
200mg/Kg bw 4.04±1.38a 62.68±14.15a 1.84±0.00b 42.73±3.48a   76.83±13.20ab    15.62±0.41ab 
Metformin 2.21±0.37a 55.88±8.66a 1.47±0.23ab 39.06±5.26a     76.46±5.59ab    12.31±0.55ab 
Normal Control 1.69±0.28a 53.30±11.10a  0.92±0.00a 37.91±3.31a     46.26±4.88a    7.35±1.28a 
 
Values are expressed as mean ± SEM (n=5). Values in the same column for same parameter with different superscripts are 
significantly different at p˂0.05. 
 
The effects of naringin on inducible nitric oxide synthase (iNOS) was assessed. The iNOS concentration was 
significantly (p<0.05) reduced in diabetic control group as compared to normal group. There were significant 
(p<0.05) increases in the hepatic concentration of iNOS with naringin and metformin treatments with 50 and 
200mg/kg giving a similar result to that of normal group. 
 
 
     FIGURE 1. Effects of Naringin on iNOS                          FIGURE 2. Effects of Naringin on urea 
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          FIGURE 3. Effects of Naringin on BCL-2                     FIGURE 4. Effects of Naringin on Caspase 3 
 
 
 
FIGURE 5. Effects of Naringin on Cas9 
 
The relative expression of hepatic BCL-2, caspases 3 and 9 were assessed in relation to apoptosis. There was a 
significant increase in  BCL-2 expression in  diabetic control with  naringin treatment  significantly (p<0.05) 
reduced  the expression  to a  similar  expression  level  of  normal  control.  Metformin however,  significantly 
(p<0.05) increased BCL-2 expression when compared to diabetic and normal control groups.   There was no 
significant change in the expression of caspase 3 when comparing the diabetic and normal control groups. 
Treatment with naringin and metformin however, significantly increased the expression of this executor.  A 
significant (p<0.05) reduction of caspase 9 was shown in diabetic control group when compared to normal. 50 and 
100mg/kg naringin treatment significantly (p<0.05) increased caspase 9 expression with metoformin treatment 
giving a similar expression to that of the normal control group. 
DISCUSSION 
In innate immune system, macrophages are vital cells that produce inflammatory cytokine  which mop up 
apoptotic cells. In performing this function, there is an increased production of nitric oxide (NO) which is generally 
produced by iNOS [17]. iNOS is rarely expressed in cells but plays a significant role in producing NO which carries 
out its cytotoxic effects on unwanted cells through its affinity for protein-bound iron [18].  From this study, the 
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reduced plasma concentration of iNOS in diabetic control group when compared with normal and treated group 
could be attributed to an increased endoplasmic reticulum stress caused by hyperglycemia as reported recently [19]. 
iNOS has been suggested to play an important role in alleviating plasma ER stress thus, low concentration of iNOS 
reduces the production of NO in macrophages and a possible increase in ER stress [19]. The reduced concentration 
of iNOS leading to decreased production of NO could explain the subsequent increase in anti-apoptotic member 
BCL-2 and inactivation of apoptosis in diabetic control group. 
The mechanism  of apoptosis  in  T2DM  is not  well  understood  with  various  results  been  reported.  Β-cell 
apoptosis has been implicated in T2DM in previous studies [6, 21, 22]. Increased expression of anti-apoptotic BCL-
2 correlates with the decreased expression of initiator, caspase 9 and effector, caspase 3 when compared to the 
treated and normal groups which can be best explained as BCL-2 inhibition of apoptosis by inactivating caspases in 
diabetic rats. This result does not correlate with previous findings of increased apoptosis in T2DM cases [22, 23, 
24]. 
Hyperglycemia in T2DM is known to cause increased production of free radicals which interact with membrane 
lipids. This result correlates with that of the study with a significant increase in diabetic control TBARS level when 
compared to normal control. In addition hyperglycemic states cause a rise production of electron donor in form of 
NADH/H+ from important tissues including the muscle and β-cell of pancrease [25]. The electron donor allows 
single electrons to be transferred to oxygen as against the normal pair of electron producing radicals instead of 
water [26]. The overproduction of free radicals in T2DM is expected to reduce antioxidant enzymes’ activities. 
Glutathione is regarded as the most important antioxidant system and depletion of the system could cause damage 
by excessive production of free radicals. This was shown from the study with decreased activities of GRx, GST and 
GPx in the organs. GPx and GRx play important roles in the glutathione system of antioxidant activities while GPx 
is also involved in inactivating H2O2 [27]. The reduction of these two enzymes correlatewith GSH depletion a 
result that has been implicated in T2DM [28]. Naringin ability to ameliorate oxidative stress in this study seemed 
to be dose dependent with 200mg/kg bw giving result close to normal control. 
Increased  liver  function  enzymes abnormalities  are common  in  cases of T2DM with  suggestion that liver 
function tests could be markers for diabetes mellitus [29, 30]. The significant (p<0.05) increase in plasma ALP and 
AST of diabetic control compared to normal could be attributed to organ damage thus allowing the release of the 
enzymes into circulation. However, treatment with naringin showed a significant (p<0.05) reduction with result 
similar to normal control which could point to the hepatoprotective effect of the flavonoid [31]. However, hepatic 
cells specific enzyme, ALT showed no significant (p>0.05) change in all treatment groups even though diabetic 
control group showed an increase compared to normal control. The result is in correlation from a recent study that 
rated the prevalence of the enzymes’ concentration as described by Mathur et al.[32] AST prevalence was the 
highest, followed by that of ALP and ALT. Excessive production of fatty acid in T2DM cases may have a concurrent 
hepatoxic effect leading to metabolic irregularities, mitochondria dysfunction amongst others. In addition, increased 
proinflammatory cytokines and lipid peroxidation may underline the increased production of liver function enzymes 
[32]. There was a dose dependent decrease in LDH and γ-glutamyltransferase (γ-GGT) levels when treated with 
naringin from the study. Elevated LDH and γ-GGT in diabetic group can be attributed to organ damage from 
hyperglycemia and dsylipidemia. This finding is consistent with that of Ishak et al. [33]. 
In addition, kidney diseases have been reported in diabetic patients which is characterised by an  increased 
concentration of urea and creatine kinase [34]. This correlates with the result from this study as in diabetic 
control group showed increased concentration of urea and creatine kinase (CK). However, naringin treatment 
showed no significant change in CK concentration but ameliorated the effects of high urea concentration at both 50 
and 200mg/kg. 
CONCLUSION 
This study has been able to add to existing knowledge in terms of the effects of naringin in T2DM. In addition 
to antioxidant  properties,  hepatoprotective  effects  and potential nephroprotective properties  were explored. 
Naringin from the study seem to produce an inverse effect to that of diabetic control thus indicating a role in 
apoptosis and mechanism of action. More research studies should be carried out to explore the relationship between 
oxidative stress and apoptosis and possible effects of flavonoids. 
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